fbpx Dual perspectives of managing depression in Mexico – an interview with Dr Arturo Lopéz and Dr Juan-Carlos Maradiaga | Progress In Mind

Dual perspectives of managing depression in Mexico – an interview with Dr Arturo Lopéz and Dr Juan-Carlos Maradiaga

Dr Lopez, from Mexicali, and Dr Maradiaga, from León, described their experiences of treating depression in their respective private practices in México during the 2016 ECNP congress in Vienna. While their approaches were broadly similar, some interesting differences also became apparent.

In the past 30 years, what do you think are the most significant advances that have been made in treating depression?

For Dr Maradiaga, the pharmacology and advances in the therapies available were cited as significant advances that had been made in the past 30 years. In addition to this, Dr Lopez included dual and multimodal approaches to patient therapy as major breakthroughs.

What proportion of your patients experience remission, and how do you define it?

Sometimes you become a companion in their suffering.

The attainment of remission using pharmacological intervention alone was being seen in 70% of Dr Lopez’s patients. In the remaining 30% of patients, psychotherapy was added to pharmacotherapy to better help patients achieve remission. However, co-morbidities such as stress, anxiety, addiction, personality disorders and post-traumatic stress disorder often made the attainment of remission very hard to achieve. As he stated, you try everything to help the patient but in some there are very small gains and sometimes you become a companion in their suffering.

Dr Maradiaga broadly agreed. In his clinic, he was able to attain remission of symptoms, such that patients could function and socialize as well as anyone else, in approximately 60% of patients. However, he, too, had a small group of maybe 5% on patients for whom nothing seemed to work.  In such cases, he would suggest the patient undergo genomic testing for optimal selection of the most suitable pharmacotherapy. It is an expensive test, but in non-responders it is one way to ensure the patient receives the therapy with the greatest chance of success.

Do you look for cognitive symptoms in depressed patients and, if so, how?

Use of all the little, everyday things helps give hints as to how a patient is progressing.

Both clinicians looked for cognitive symptoms in their depressed patients. Dr Maradiaga compared cognition before and after therapy both directly, by interviewing the patient, and indirectly, by interviewing their spouse or carer. Simple questions like asking whether patients could read a book or watch a movie can help ascertain whether cognition was deteriorating or stabilizing.

Dr Lopez principally used clinical interviews and acute observation to ascertain cognitive function. How the patient talks, responds to questions, their attentiveness, is their memory span poor allows an idea of the patient’s cognitive abilities to be made. Use of all the little, everyday things helps give hints as to how a patient is progressing.

You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente agli Operatori Sanitari (medici e farmacisti). I contenuti di questo sito sono prodotti da un team di Operatori Sanitari il cui obiettivo è presentare le ultime novità in ambito psichiatrico e neurologico, attraverso interviste, registrazioni audio/video di seminari con opinion leader, report e sintesi di congressi sia internazionali che nazionali. Per poter accedere al sito è quindi necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Operatore Sanitario.
Per accedere alla pagina si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi. La pagina per la quale sta richiedendo l'accesso ospita materiale formativo comunque attinente all'impiego di medicinali prodotti o commercializzati da Lundbeck. Con riferimento al Decreto Legislativo n.219 del 24 aprile 2006 e s.m.i., art. 119, art. 121 comma 1 e art. 124 commi 4 e 8, Lundbeck limita l'accesso ai contenuti presenti nella pagina PIM Academy a medici specialisti e farmacisti ospedalieri.
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country